Clinical Trial Update: Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigates a combination of sorafenib, tamoxifen, and cisplatin for high-risk stage III melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Nexavar (Sorafenib)
• Nolvadex (tamoxifen)
• Platinol (cisplatin)

Snippet

Sponsor: San Diego Pacific Oncology & Hematology Associates | Conditions: Melanoma (Skin) | Phase 2 | Status: UNKNOWN